12:00 AM
Apr 04, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Soluble Ferric Pyrophosphate: Phase III started

Rockwell began the double-blind, placebo-controlled Phase III CRUISE-1 trial in 300 patients to evaluate 11 µg/dL SFP delivered via dialysate 3-4 times weekly for up to 12 months....

Read the full 118 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >